Healthcare Industry Insights

Tuesday, 28 January 2020

Nanomedicine Market: Industry Analysis and Outlook Report

The global Nanomedicine Market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc. Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/nanomedicine-market

Further key findings from the report suggest:

Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices
These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation
Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share
In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment
Introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity are attributive for projected progress
Clinical cardiology is expected to witness the fastest growth through to 2025 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis
Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for revenue generation from European economies
Asia Pacific is estimated to witness the fastest growth over the forecast period
Factors responsible include government and regulatory authorities that have implemented a framework to encourage R&D collaborations and framework extension.
Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck
Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position

North America dominated the industry in 2016, accounting for a 42% of total revenue
Presence of key participants operating in the region are involved in collaborative activities are attributive for the largest share of North America in sector revenue

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

CPOE Market Size Projected To Reach $1.9 Billion By 2024

The global Computerized Physician/Provider Order Entry (CPOE) Market is expected to reach USD 1.9 billion by 2024, according to a new report by Grand View Research, Inc. Government and other independent healthcare organizations are striving to streamline care delivery process with the prime objectives of bringing automation, reducing errors, and bringing an overall reduction in clinical decision time especially in the developed economies. CPOE provides a viable platform to support aforementioned objectives. Hence, promotion by government agencies as well as healthcare organizations is spurring the growth of the CPOE market. In addition, increasing incidence of medication errors, caused by poor legibility, communication, and patient misuse, favor the implementation of CPOE. Furthermore, consistent influx of technologically advanced systems such as integrated CPOE with added benefits such as inventory management and easy documentation, act as a vital driver of CPOE market growth.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/computerized-physician-order-entry-cpoe-market

Further Key Findings from the Study Suggest:

The computerized physician order entry (CPOE) services sub-segment dominated the component segment in 2015. Enhanced outsourcing of several services coupled with increasing involvement of the professional skills contributed to their growth as compared to CPOE hardware and software sub-segments. Moreover, outsourcing renders increased process efficiency along with development of core competencies and reduced costs.
Integrated CPOE systems held a substantial share of more than 70.0% in 2015. Also, this segment is projected to witness lucrative growth over the forecast period, which can be attributed to their competent connectivity across various functionalities such as nursing, pharmacy, and procurement.

Web-based deployment delivery mode segment witnessed highest demand in 2015, increasing penetration of internet services and augmented digital literacy contributed to emergent demand for these services.

On the other hand, cloud-based delivery systems are anticipated to gain substantial market share over the forecast period. These systems are facilitated with features such as remote data access and data security which render a competitive edge over other systems.

Hospitals led the end-use segment and are also expected to witness lucrative growth in the next 8 years. Greater volume of patients as compared to other end users is the prime factor responsible for high preference of hospitals thereby driving the market growth.

North America, especially the U.S., with its advanced healthcare systems and early adoption of several advanced technologies held a commanding share of more than 50.0% in the global CPOE market. Availability of supportive infrastructure and presence of leading market players in this region positively influenced this region’s growth.

Asia Pacific is projected to grow with a sturdy rate over the forecast period. Large target population base coupled with increasing preference for advanced technological platforms and high unmet needs present market players with the opportunity to invest in this region.

Some of the key players in this market include IBM, Oracle Corporation, SAS, Cerner Corporation, Allscripts, OptumHealth, and Verisk. The notable initiatives in the industry include new product launches, collaboration with government bodies, and investments in R&D.

About Grand View Research

Monday, 27 January 2020

Artificial Ventilation and Anesthesia Masks Market by Key Players, Application and Forecast Report

Global Artificial Ventilation And Anesthesia Masks Market is expected to reach USD 2,888.8 million by 2022, according to a new report by Grand View Research, Inc. Key factors attributing to market growth include rising number of operation and emergency room procedures coupled with growing demand novel products which can be used to carry out intubation process without removing the oxygen mask. Increase in the target disease has a direct impact on the number of operation room, emergency and intensive care procedures and is expected to boost usage rates of ventilation masks over the forecast period.

Increasing geriatric population is a major factor increasing the prevalence rate of several diseases. Additionally, growing prevalence of sleep apnea is one of the most significant growth drivers for these anesthesia and ventilation masks over the forecast period.

According to statistics published by the National Sleep Foundation in 2012, around 40 million Americans were affected by chronic sleep disorders. Furthermore, these patients are at a high risk of visiting emergency department and intensive care units, and as a consequence are expected to increase the demand of ventilation masks in the next seven years.

The market dynamics indicate that various players operating in this space compete on the basis of product specification and prices. The technology used to manufacture, quality of the product, and patient comfort are the key variables expected to impact the usage of these products. The healthcare providers assess the risk to the patient and determine the need to use invasive ventilation or non-invasive ventilation. The use of non invasive masks in accident and trauma cases, lung failure and other emergency cases is a key factor contributing to the high usage rates of these products.

The market is segmented on the basis of application as operation room, intensive care units, emergency room, dental, and home care. In 2014 operating room held the maximum share of over 58% for low risk procedures and is expected to be the largest segment in the next seven years. Increase in insurance penetration, number of hospitals and dental centers to tap the high unmet needs in emerging economies is a key factor expected to boost the surgical volume and therefore these factors are expected to increase the demand for ventilation masks over the forecast period.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/artificial-ventilation-anesthesia-masks-market

Further key findings from the report suggest:

In 2014, North America dominated the overall market with a share of more than 50%. Key factors attributing to its large share include presence of robust healthcare infrastructure, which includes hospitals, emergency and dental centers.
Furthermore, in the U.S., the Affordable Care Act is a key driver encouraging millions of patients to opt for surgical treatments and utilize other healthcare services, and as a result is expected to boost usage rates of artificial ventilation and anesthesia masks over the forecast period.
Asia Pacific is expected to be the fastest growing market over the forecast period. Key factors attributing to its high growth are increase in public and private healthcare expenditure to build new hospitals, improve reimbursement scenario which lead to improvement in overall healthcare indicators.
Additionally, large population affected with various diseases is expected to increase the number of emergency, ICU and operating room procedures and as a result are expected to increase usage rates in these markets.
Key players operating in the market include Phillips Respironics, ResMed, Fisher & Paykel, CareFusion, Ambu, Drager, and others. These companies have an extensive portfolio of ventilation and CPAP masks.
Additionally, emergence of new players with novel product offerings such as SuperNO2VA from RMDevices is expected change market dynamics due to its ability to carry out inhalation anesthesia, artificial ventilation and intubation procedure simultaneously.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Genomics In Cancer Care Market Worth $9.22 Billion By 2022

Global Genomics in Cancer Care Market is expected to reach USD 9.22 billion by 2022, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer coupled with adoption of next generation sequencing for the diagnosis & treatment is expected to fuel the market with future growth opportunities. Increasing incidences of cancer triggers the demand for cost effective and accurate diagnostics in coming years.

In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/genomics-in-cancer-care-market

Further key findings from the study suggest:

Instrument segment dominated the overall market in terms of revenue share as of 2014 and accounted for 33.4% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.
Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.
Drug discovery and development segment is expected to show lucrative CAGR of 17.6% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.
Genome sequencing held the dominant share of technology segment as it is most prominently used for diagnosis due to associate benefits such as faster and accurate method. It is expected to show significant growth rate of 17.5% in coming years owing to remarkable decrease in the cost for genome sequencing and increasing adoption rates.
The cancer research segment held the largest share of 34.1% in 2014 due to increasing demand for faster & accurate diagnostic methods to treat variety of cancer. Other use such as commercial adoption of genetic testing is expected to be fastest growing segment owing to increasing demand of cancer genomic testing to fulfill unmet needs in healthcare sector.
Some key players operating in this market include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology., PerkinElmer, Qiagen, and GE Healthcare.

About Grand View Research

Malaria Diagnostics Market Size, Share & Trends Analysis Report By Technology

The global Malaria Diagnostics Market size is projected to reach USD 998.85 million by 2026 expanding at a CAGR of 5.4%, according to a new report by Grand View Research, Inc. Rising prevalence of the tropical disease in endemic countries, development of novel diagnostic techniques, and rising investments by regional governments and private investors are expected to propel market growth. Malaria is one of the most widespread life-threatening diseases, commonly occurring in the tropical and subtropical regions due to changing climate, low economic growth, underdeveloped healthcare infrastructure, and lack of access to advanced treatment.

Increasing number of government initiatives and investments by market participants are also anticipated to fuel market growth in the near future. A large number of malarial elimination programs are being undertaken by major companies to reduce the disease prevalence. For instance, Novartis’s Malaria Initiative was aimed at facilitating malaria elimination and control.Along with various organizations, the company has provided non-profit treatment to 750 million people across 60 countries. Thus, such initiatives are anticipated to facilitate the development of novel technologies and aid in market penetration.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/malaria-diagnostics-market

Further key findings from the study suggest:

Conventional usage of microscopic examination for detection of malarial parasite has driven the microscopy technology segment
RDTs are anticipated to account for the largest revenue share owing to ease of usage, convenience, and rapid diagnosis
Molecular diagnostic tests is projected to be the fastest-growing technology segment during the forecast period owing to their accuracy and capability of detecting low parasite count
Africa led the malaria diagnostics market in 2018 due to high disease incidence and increased adoption of various malarial diagnostic techniques in the region
Southeast Asia also held a considerable revenue share in 2018 owing to high disease reoccurrence and initiatives undertaken to curb malarial incidence
Few key companies include Access Bio, Inc.; Alere, Inc.; Premier Medical Corporation Ltd.; Sysmex Partec GmbH; bioMérieux, Beckman Coulter, Inc.; Siemens Healthcare; and Leica Microsystems

About Grand View Research

Friday, 24 January 2020

Neuroscience Market Trends, Growth Opportunities and Overview Report

Global Neuroscience Industry demand was worth USD 24.09 Billion in 2013 and is anticipated to reach above USD 30.80 billion by 2020. Rising investment in R&D resulting in the development of numerous products in the neuroinformatics coupled with adequate funding from the government are key factors that drive growth in this market.

Neuro-informatics involve designing and developing efficient tools and algorithms that can augment the performance of structural and functional mapping. Global Neuroscience market is expected to grow at CAGR of 2.9% over the next seven years.

Increasing occurrence of malicious disorders including Parkinsonism and Alzheimer’s disease together with other inherited CNS disorders has resulted in increased necessity for new improvements in neuroscience industry. The market is expected to experience growth over the forecast period on account of growing demand in laboratories and academic centers. The market players aim at introducing unique technologies with the ability to obtain insights to understand better the compound nervous functionalities and neural manipulations. Furthermore, increasing aggregate geriatric population every year is anticipated to drive significantly the demand owing to a growing need for better treatment and medication.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/neuroscience-market

Rising demand for imaging machines & microscopic devices and intraneural imaging tools for visualization of intra-neural links is also foreseen to serve as a growth driver for this industry over the forecast period. In 2013, electrophysiology technology, whole brain imaging and neuro-microscopy equipment intended for neuroscience research collectively formed the chief revenue producing units owing to rapid advancements in these techniques that allow brain imaging with single cell resolution PET, MRI, and other advanced microscopes are expected to witness substantial growth due to expected developments in near future.

Neuro-cellular manipulation and neuro-proteomic analysis are estimated to record fastest growth rate of over 3.5% owing to improvements regarding disease etiology over the forecast period. Instrumentation of technology modules for Neuroscience market accounted for the largest share of the market in terms of revenue as a result of highly priced instruments used in neuro-analytical testing. Also, data analysis and software implements are predicted to observe a significant growth in the next seven years on account of efficient data tracking algorithms and methodologies.

In 2013, North America emerged as the largest regional market contributing to over 40.0% of the overall revenue owing to extensive ongoing research projects assisted by government universities. Furthermore, the surge in the incidence of CNS-related disorders in the regional population is expected to propel growth in the next seven years.

The Asia Pacific industry for neuroscience is estimated to grow at a CAGR of nearly 3.0% over the forecast period to reach a revenue over USD 8.00 billion by 2020. The increase in patient awareness coupled with the presence of unmet medical needs on nervous system syndromes is expected to drive market growth. In addition to increasing healthcare expenses in emerging markets of China and India are anticipated to propel growth in demand.

Key companies include Sutter Instrument Corporation, Trifoil Imaging Inc., Newport Corporation, Femtonics Ltd., Neurotar Ltd., Scientifica Ltd, Intan Technologies, AxionBiosystemsNeuralynxInc, Blackrock Microsystems LLC, Thomas Recording GmbH, LaVisionBiotec GmbH, PlexonInc, Mediso Medical Imaging Systems, NeuroNexus Technologies and Alpha Omega.

The market is characterized by intense competition on account of growing number of firms and extensive R&D. Companies in the market emphasize on new developments using advanced technology to differentiate and trace neural mechanisms.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

ECG Equipment Market Size To Reach $6.3 Billion By 2022

The global ECG Equipment Market is expected to reach USD 6.3 billion by 2022, according to a new report by Grand View Research Inc. The rising incidences of cardiovascular disorders and government initiatives to make people aware about health check-ups are expected to boost market growth. In addition, the change in the medical preference from acute intervention to preventive care is expected to increase the demand for more accurate and cost-effective methods for heart monitoring.

According to the WHO, in 2012, around 17.5 million people died due to cardiovascular diseases. This is due to the late diagnosis and absence of early symptoms as the patient fails to keep record of his vital signs.

Owing to the increasing incidences, government is undertaking various awareness programs. According to the American Heart Association (AHA), 56% women identified heart disease as a leading cause of death in 2012 as compared to 30% in 1997.

Access Research Report of ECG Equipment Market @
http://www.grandviewresearch.com/industry-analysis/ecg-equipment-market

Further key findings from the report suggest:

· ECG monitoring equipment has high future growth potential owing to changing trend towards preventive care and new product innovation with data integration. In February 2014, Medtronic launched its FDA approved Reveal LINQ. The upgraded version of Reveal XT offers patient heart monitoring for three years with 20% more data memory than its previous version.

· ECG stress testing systems is one of the dominating segments of the market. The growing need for flexible stress systems and comprehensive data management is driving the market for this segment. Quinton 9500 series from Cardiac Science portable system allows physicians to optimize the examination space and enables more data integrations.

· Holter monitoring systems is another segment, which is expected to gain significant market share over the forecast period due to the fact that the system assists in identifying arrhythmias that takes place during certain activities such as exercise, stress, bowel movements, sleep, eating, and stress

· 2M Engineering Ltd. launched the VitaMove 2S ExG movement and ECG-recorder, which is equipped with 3-lead ECG holter, that combines daily activities with heart rate events/trends, ECG, and derivatives such as Heart Rate Variability (HRV)

· North America dominated the market in 2014 and is expected to grow at a CAGR of 5.8% over the forecast period. With major industry players situated in North America, the innovations and upgrading rates are higher as compared to other regions. In August 2015, InfoBionic along with Safeguard Scientists raised USD 8 million to commercialize Mome Kardia. Mome Kardia is a remote patient monitoring system based on the cloud technology that could be worn around the neck.

· Asia Pacific is expected to witness substantial growth during the forecast period owing to the rising incidence rate of heart diseases and growing manufacturing outsourcing in the region

· According to the Government of India, the prevalence of heart failure in the nation due to hypertension, obesity, coronary heart disease, obesity, rheumatic heart disease, diabetes ranges from 1.3 to 4.6 million and an annual incidence rate of 491,600 to 1.8 million

· As per a report published by the Associated Chambers of Commerce and Industry of India (ASSOCHAM), people have adopted unhealthy lifestyles along with increasing stress levels, decreasing physical activity, tobacco smoking, and increasing consumption of saturated fats

· Industry players are constantly fueling the market with newer technologies or upgrading existing technology. In May 2015, CardioComm Solutions, Inc. launched HeartCheck PEN. This Bluetooth wireless connectivity pen could be connected for data acquisition with Android and Apple smartphones.

· Apart from technology innovations, many industry players are expanding their global presence by signing distribution agreements with domestic distributors. In October 2015, iNeedMD Holdings, Inc. signed a distribution agreement with Clifton Africa Ltd. This one-year distribution agreement is worth USD 1.5 million.

· Key players of the ECG equipment market include Medtronic, GE Healthcare, Philips Healthcare, Schiller AG, Nihon Kohden, CardioComm Solutions, Inc., and Johnson & Johnson

About Grand View Research

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com